



Market Announcement

31 July 2023

The Hydration Pharmaceuticals Company Limited (ASX: HPC) – Trading Halt

Description

The securities of The Hydration Pharmaceuticals Company Limited ('HPC') will be placed in trading halt at the request of HPC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 2 August 2023 or when the announcement is released to the market.

Issued by

Dale Wang

Adviser, Listings Compliance

For personal use only

31 July 2023

ASX Compliance Pty Ltd
Level 50, South Tower
Rialto, 525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

The Hydration Pharmaceuticals Company Limited (ASX: HPC) Request for Trading Halt

Pursuant to Listing Rule 17.1, The Hydration Pharmaceuticals Company Limited ACN 620 385 677 (the **Company** or **HPC**) requests that ASX grant an immediate trading halt for all of HPC's securities.

In accordance with Listing Rule 17.1, the Company advises that:

1. the trading halt is requested pending an announcement regarding a capital raising, to be undertaken by way of a share placement and pro rata, non-accelerated, non-renounceable entitlement offer (**Offer**);
2. the trading halt is required to enable the Offer to be undertaken in an orderly manner;
3. HPC requests that the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the Offer and the commencement of trading on Wednesday, 2 August 2023.
4. HPC is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market or ASX about the trading halt.

ENDS

This trading halt request was authorised for release by the Board of HydraLyte North America.

For more information please contact:

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

About The Hydration Pharmaceuticals Company Limited

The Hydration Pharmaceuticals Company Limited (HPC) is a well-known brand developed in Australia in 2001 to produce a range of electrolyte-rich tablets, liquids and powders and aims to grow its footprint in new international markets, led by an experienced management team and high skilled Board of Directors. HydraLyte North America does not operate in Australia or New Zealand, where the brand is owned by Care Pharmaceuticals, but has exclusive rights to the HydraLyte brand in North and South America, Europe (excluding Turkey), China (excluding Taiwan) and Hong Kong. Current operations are focused on the United States and Canada, with headquarters in San Diego, California.